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1. Introduction 
Lung cancer is one of the most common malignancies worldwide and a leading cause of 
cancer-related deaths. It is increasing year by year in almost all areas of the world, except for 
a slight decrease in certain countries [1]. Lung cancer consists of heterogeneous groups in 
terms of pathological features and is commonly classified into the following two major 
types, small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). 
NSCLC also is a group of heterogeneous histological types, the majority of which are 
squamous cell carcinoma (SQC) and adenocarcinoma (ADC) with roughly similar 
frequencies (30-40% each), and large cell carcinoma (LCC) with a lower frequency (< 10%). 
SCLC comprises nearly 20% of lung cancer. ADC and LCC are further sub-classified into 
several categories, respectively. The classification of lung cancer is not only of academic 
interest but also of practical necessity, because the biological aggressiveness, responsiveness 
to therapeutic intervention and patients’ prognosis are greatly different among the 
respective types [2]. 
Lung cancer originates from the airway epithelia of larger and smaller bronchi as well as of 
alveoli. While it is generally accepted that cancer cells are derived from progenitor or tissue 
stem cells, relatively little has been elucidated with regard to the identification of airway 
stem cells and the molecular mechanisms underlying their self-renewal and differentiation 
abilities [3-5], in contrast to other epithelial tissues such as the intestine, mammary gland, 
and skin [6]. 
The heterogeneity of lung cancer likely reflects differences in the site of origin (proximal 
versus peripheral), and, more importantly, in the type of cell of origin, i.e., progenitor (tissue 
stem) cells. The diversity of etiologic factors and target genes, the types of genetic insults, 
and the ensuing effects, activation or inactivation, on the genes involved, would also be 
responsible for the heterogeneity of lung cancer. In fact, tobacco smoke, containing more 
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than 60 carcinogens, is generally accepted as the most important cause of almost all types of 
lung cancer, among which the genetic and molecular mechanisms of carcinogenesis differ 
considerably. The ensuing genetic alteration and epigenetic changes as well, could lead to 
dysfunction of molecular signal transduction pathways, which relate directly or indirectly to 
proliferation, differentiation, and death of the cell. 
In our recent review article, we underscored that silencing alterations of both the RB and 
TP53 genes are most likely to be important and early events in the development of SCLC, 
whereas alterations of the epidermal growth factor receptor (EGFR) signaling pathway play 
significant and important roles in NSCLC carcinogenesis [7]. We also emphasized that 
alterations of both the RB and TP53 genes are central to the carcinogenesis of SCLC, while 
many other factors including achaete-scute complex homolog 1 (ASCL1) and thyroid 
transcription factor-1 (TTF-1) contribute to the development and biological behavior of 
SCLC [8]. 
The cancer stem cell (CSC) theory has proposed that a tumor cell subpopulation possessing 
self-renewal capacity which forms only a small fraction of tumor tissue is central in 
sustaining neoplastic lesions and is a potentially crucial target of cancer therapy [9-23]. The 
CSCs are possibly produced by either transformation of normal stem cells or multistep 
dedifferentiation of specialized progenitor cells through a progressive accumulation of 
genetic aberrations. Rapp, et al. [12] proposed a model of oncogene-induced plasticity for 
CSC origin by demonstrating reprogramming events triggered by a specific combination of 
oncogenes. Li, et al. [16] suggested that genomic instability is a driving force for 
transforming normal stem cells into CSCs and, in CSCs, a potential mechanism for cancer 
cell heterogeneity. The origin of CSCs and this mechanism are discussed in more detail in 
other chapters [The publisher may modify this part]. 
The CSCs of lung cancers can be considered to originate from either airway stem cells, 
which have not been identified yet, or respective committed progenitor cells, such as 
bronchioloalveolar progenitor cells, basal/mucous secretory bronchial progenitor cells, and 
neuroendocrine progenitor cells (see the section Origin of CSCs in lung cancer). 
The CSC theory is tremendously attractive to both researchers and physicians, because the 
CSC is central to cancer cell biology and cancer therapy. The discovery of specific markers of 
CSCs in the respective types of cancers is particularly important. Furthermore, it is 
necessary to clarify the function of these molecules, as the disruption of the signaling 
pathways and gene transcriptions that control the activity of CSCs is the final goal of CSC-
targeting therapy. We emphasized that a knowledge of CSC signaling pathways may lead to 
new treatment that kill or induce differentiation of CSCs and could better contribute to cures 
[24]. These treatments could be designed to target CSCs in order to induce the 
differentiation of CSCs, or eliminate CSCs by inhibiting the maintenance of the stem-cell 
state. For instance, side population (SP) cells that are considered to represent CSCs (see 
below), of a human lung cancer cell line (A549) totally disappeared after treatment with the 
selective ATP-binding cassette transporter G2 (ABCG2) inhibitor fumitremorgin C [25]. As 
another example, a Hedgehog signaling inhibitor cyclopamine strikingly reduced the in vitro 
invasive capacity of pancreatic cancer cell lines and also profoundly inhibited metastatic 
spread in an orthotopic xenograft model [26]. 
In regard to lung cancer, we also stressed the extreme importance of identifying specific 
CSC markers for the respective subtypes of lung cancer, for instance SCLC and NSCLC 
(ADC, SQC, LCC, and others), since they are quite different not only in phenotype but also 
in pathogenesis and biological behavior. In particular, SCLC is highly metastatic, drug-
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resistant, and rapidly fatal. The aggressiveness of SCLC may be attributable to an 
abundance of CSCs, as CSCs are drug-resistant and play a crucial role in cancer recurrence 
and metastasis. Alternatively, it is also possible that the CSCs of SCLC are endowed with 
specific biological properties, for instance niche-independency or strong drug-resistance, or 
both. If SCLC-specific CSC markers were discovered, they would be extremely useful as 
targets of chemotherapy, for the establishment of therapeutic regimens, and for predictions 
of the prognosis (outcome) of patients. 
In this chapter, we discuss the characteristics of normal airway stem/progenitor cells and 
CSCs in lung cancer by reviewing hitherto described study results. In addition, we 
demonstrate the potentially distinct differences in the mechanism of maintenance of CSCs 
between SCLC and NSCLC, primarily focusing upon aldehyde dehydrogenase (ALDH) 
based on our own experiments currently underway. 
2. Stem cells in healthy and injured lung 
Although the airway stem cell in a strict sense has not been identified yet, several lines of 
evidence support the existence of regional progenitors cells, such as bronchioloalveolar 
progenitor cells, basal/mucous secretory bronchial progenitor cells, and neuroendocrine 
progenitor cells, which maintain normal homeostasis as well as play roles in repair [3-5]. 
These progenitor cells expand their populations in response to various insults including 
toxic substances, but do not become tumorigenic unless at least one genetic or epigenetic 
event occurs, for instance by tobacco smoke carcinogens [4,27]. 
3. Origin of CSCs in lung cancers 
As in hematological malignancies and other solid cancers, the presence of subpopulations of 
cells endowed with CSC properties has been recognized in lung cancers. Like CSCs in other 
tissues, the CSCs of lung cancers can be considered to originate from either airway stem 
cells, which have not been identified yet, or respective committed progenitor cells, such as 
bronchioloalveolar progenitor cells, basal/mucous secretory bronchial progenitor cells, and 
neuroendocrine progenitor cells [3-5], resulting in the initiation of region-specific lung 
cancers [4]. 
4. Cell markers for CSCs in lung cancers 
CSC markers for lung cancer are a matter of some controversy, probably reflecting the 
tremendous heterogeneity of lung cancers in terms of cell of origin, etiology, pathology, 
biology, and molecular/genetic pathogenesis [2,7]. We herein briefly discuss these markers, 
paying special attention to the differences between SCLC and NSCLC; representative lung 
CSC markers reported to date are listed in Table 1. 
5. CD133 
CD133 was first reported as a novel marker for human hematopoietic stem and progenitor 
cells [28], and later found in some types of leukemic cells [29]. Prominin-1, which was 
identified on neuroepithelial stem cells in mice in 1997, is a mouse homolog of the human 
CD133 antigen [30]. The expression of CD133 has been detected in human central nervous 
system stem cells [31], human trophoblasts [32], human lymphatic/vascular endothelial 
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precursor cells [33], and human prostatic epithelial stem cells [34]. The CD133 antigen is a 
120kDa five-transmembrane domain glycoprotein, and its chromosomal location (4p16.2-
p12) and amino acid sequence have been clarified [35]. Although its function is still 
unknown, CD133 may have a role in stem cell activation/maintenance, as shown by its 
coexpression with β1-integrin in the epidermal basal cells [36], release of CD133-carrying 
membrane particles into the extracellular space from neural progenitors and some epithelial 
cells [37], and potential regulatory activity of cell-cell contacts [38].  
Recent studies have demonstrated that CD133 is a specific marker of CSCs in a wide 
spectrum of malignant tumors including brain tumors, colorectal cancers, pancreatic 
cancers, breast cancers, prostate cancers, ovarian cancers [39-41], and some lung cancers 
[42]. In contrast to the general consensus that CD133 is a ubiquitous CSC marker, several 
studies demonstrated that CD133-negative cells in certain human tumors also possess 
tumorigenic activity upon xenotransplantation into immunocompromised rodents [43-45]. 
These results imply that the CD133-negative subpopulation also contains cells with cancer 
initiating cell (CIC) activity. Mizrak, et al. [46] pointed out that CD133 is actually detected by 
its glycosylated epitope, AC133, and it is likely that AC133, but not CD133, is a more reliable 
CSC marker. Bidlingmaier, et al. [47] also suggested that the use of CD133 expression as a 
marker for CSC should be critically evaluated. These reports may explain the discrepancy 
observed in the results from different studies. 
In regard to lung cancers, Eramo, et al. [42] reported that CD133 is a useful CSC marker in 
both SCLC and NSCLC. In contrast, Meng, et al. [48] reported more than 45% of A549 
(NSCLC) and H446 (SCLC) cells to be CICs regardless of CD133 expression based on the 
results of cloning and tumorigenic analyses. Jiang, et al. [49] reported that, in NSCLC, cancer 
cells with strong ALDH activity (see below), showed CSC features and CD133 expression. 
Levina, et al. [50] demonstrated that NSCLC cells (H460) propagated a CD133-positive CSC-
like cell population, in association with the expression of Oct-4 and high nuclear β-catenin 
(see below), after an in vitro treatment with anti-cancer drugs. Chen, et al. [51] reported that 
CD133-positive NSCLC cell lines display self-renewal and chemo-radio-resistant properties. 
Intriguingly, in SCLC, Jiang, et al. [52] demonstrated that achaete-scute complex homolog 1 
(ASCL1) directly regulates ALDH1A1 and CD133 and that the CD133high-ALDH1A1high-
ASCL1high subpopulation exhibits the features of CSCs both in vitro and in vivo. ASCL1 is a 
specific marker of SCLC and thought to play important roles in its phenotypic expression 
and biological aggressiveness [8,53].  
6. Side population 
Hoechst 33342 dye-efflux side population (SP) bone marrow cells were first discovered as 
hematopoietic stem cells in mice [54]. Since then, SP cells with stem-cell-like capabilities 
have been found in a variety of human hematologic and solid malignancies. These cells 
show the features of CSCs characterized by self-renewal activity, differentiated progeny 
production, tumorigenicity, as well as the expression of CSC markers and stem cell genes 
[55]. Thus, SP cells can be assumed to be CSCs. Importantly, SP cells are highly resistant to 
chemotherapeutic agents and crucial in therapy resistance and tumor recurrence [55-57]. 
Zhou, et al. [58] showed that expression of the ATP binding cassette transporter superfamily 
member G2 (ABCG2) gene is an important determinant of the SP phenotype, and that it might 
serve as a marker for stem cells from various sources. SP cells are usually isolated and 
purified by fluorescence activating cell sorting (FACS) using an ultraviolet (UV) laser. 
www.intechopen.com
Cancer Stem Cells in Lung Cancer: 
Distinct Differences between Small Cell and Non-Small Cell Lung Carcinomas   
 
109 
Recently, a new technique using a Violet-excited cell-permeable DNA-binding dye has been 
reported [59]. This method is inexpensive and yields the same results as UV-excited FACS 
[59]. In contrast, Wu, et al. [55] pointed out the following problems in using the SP 
phenotype as a CSC marker: 1) cells resistant to the Hoechst dye’s toxicity do not consist 
only of stem-like cells, 2) variables in staining times, dye concentrations, and cellular 
concentrations can greatly affect the SP phenotype, and 3) cytometric gating strategies used 
to isolate SP cells lack the consistency of gating strategies used when staining with markers. 
These problems potentially lead to cross contamination of the SP and the non-SP fractions 
ultimately resulting in the production of confounding data. They emphasized that more 
stringent gating strategies are necessary and that a combination of isolation methods are 
required to enhance the purity of CSCs. 
In lung cancers, Ho, et al. [60] reported that the SP cells in NSCLC cell lines were an enriched 
source of tumor-initiating cells with stem cell properties. Sung, et al. [25] suggested that 
ABCG2 played an important role in the multidrug resistance phenotype of SP cells in a 
NSCLC cell line, A549. In contrast, Meng, et al. [48] reported more than 45% of A549 
(NSCLC) and H446 (SCLC) cells to be CICs regardless of SP features based on the results of 
cloning and tumorigenic analyses. 
7. Aldehyde dehydrogenase 
The ALDH superfamily represents a divergently related group of enzymes that metabolize a 
wide variety of endogenous and exogenous aldehydes. In the human genome, at least 19 
functional genes and 3 pseudogenes have been identified [61]. ALDH also contributes to the 
oxidation of retinol to retinoic acid, a modulator of cell proliferation, which may also 
modulate stem cell proliferation [62]. Murine and human hematopoietic stem cells [63-64], 
murine neural stem cells [65], normal and malignant human mammary stem cells [66], and 
normal and malignant human colorectal stem cells [62,67] exhibit ALDH activity and 
express this enzyme, strongly suggesting that strong ALDH activity and/or antigen 
expression can be used as a marker for stem cells in a variety of cancers. ALDH activity has 
been measured as substrate-oxidizing activity in whole cell lysate, and the expression of the 
enzyme has been detected by immunoreactions with specific antibodies, such as Western 
blot and immunohistochemical analyses. Since the development of a new method using an 
ALDH-activated fluorescent substrate as a marker for the isolation of human hematopoietic 
stem cells [68], the so-called Aldefluor assay has been widely applied to the measurement 
and isolation of normal and malignant stem-cell-like cells in a variety of tissues [49,64-67]. 
This method is useful for isolating and purifying viable cells with high levels of ALDH 
activity for assays of the CSC properties of these cell populations. 
8. Other lung CSC markers 
Koch, et al. [69] demonstrated that a majority of SCLC were immunohistochemically positive 
for the antibody against podocalyxin-like protein 1 (PODXL-1) and hypothesized that 
PODXL-1 is a potential CSC marker of SCLC. PODXL-1, belonging to a large family of cell 
surface sialomucins and being most closely related to CD34 and endoglycan [33,70,71], is 
expressed in primitive hematopoietic progenitors and thought to be a marker of embryonic 
and hematopoietic stem cells [72]. 
Gutova, et al. [73] found that SCLC cells positive for urokinase plasminogen activator 
receptor (uPAR) were resistant to traditional chemotherapies and speculated that they 
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contain a putative CSC population. Urokinase plasminogen activator (uPA) and its receptor 
uPAR are instrumental in controlling membrane-associated extracellular proteolysis and 
transmembranous signaling, thus affecting cell migration and invasion [74]. uPAR is up-
regulated by several oncogenic pathways including mutations of multiple oncogenes. 
Alfano, et al. [74] underlined the importance of uPAR signaling in the prevention of 
apoptosis. 
9. Signaling pathways in CSCs of lung cancers 
Sonic hedgehog 
Sonic hedgehog (Shh) is expressed by the epithelial cells, and binds and signals to 
Patched1/2 receptors in the underlying mesenchyme [6,75,76].  
Watkins, et al. [77] reported the significance of Hedgehog signaling in a subset of SCLCs. 
Yagui-Beltrán, et al. [78] and Peacock, et al. [79] reviewed the results of studies on CSC 
markers and signaling pathways in pulmonary carcinogenesis with special attention to the 
differences between SCLC and NSCLC. Both papers emphasized the potential importance of 
the Hedgehog and Wnt signaling pathways in SCLC and NSCLC (see below). Interestingly, 
human primary or immortalized bronchial epithelial cells exposed to cigarette smoke for 
only eight days in culture became tumorigenic in nude mice, in association with the 
activation of the Hedgehog and Wnt signaling pathways [80].  
Wnt signaling pathway and nuclear β-catenin 
For the maintenance and activation of normal stem cells, the Wnt/β-catenin signaling 
pathway is crucial, as distinctly demonstrated in the intestinal mucosa epithelia, epidermis, 
mammary gland [6], and other tissue [81]. The importance of Wnt signaling in cancer cells 
has been emphasized [82], and the Wnt/β-catenin signaling cascade is a critical regulator 
not only of normal stem cells but also of CSCs [83]. Disruption of this signaling pathway at 
any step potentially causes disorders of stem cell activity and plays a crucial role in the 
development of cancer. For instance, sustained Wnt signaling mediated by the membrane 
receptor Frizzled stimulates the release of β-catenin from a cytoplasmic degradation 
complex composed of APC, Axin, GSK3-β and Dsh, resulting in its movement into the 
nucleus and activation of Lef/Tcf transcription factors for c-Myc and cyclin D1 [82]. As 
another example, inactivation of APC due to a gene mutation also results in the release of β-
catenin from the degradation complex, leading to the neoplastic transformation of colonic 
epithelial stem cells [11]. Thus, nuclear β-catenin is a hallmark for active Wnt signaling [75]. 
As described above, Yagui-Beltrán, et al. [87] and Peacock, et al. [79] emphasized the 
potential importance of the Wnt signaling pathway in SCLC and NSCLC in addition to the 
Hedgehog signaling pathway. Also as described above, human primary or immortalized 
bronchial epithelial cells exposed to cigarette smoke became tumorigenic in nude mice, 
being associated with the activation of not only the Hedgehog signaling pathway but also 
the Wnt signaling pathway [80]. 
Other signaling pathways and transcription factors in lung CSCs 
While the Wnt/β-catenin signaling pathway has been extensively investigated in many 
tissues including the lung, other signaling pathways are also important for controlling stem 
cell activity, including transmembranous Notch signaling and bone morphogenetic protein 
(BMP) signaling mediated by the cell membrane receptor Bmpr1a [8,75]. However, we are 
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only beginning to understand the roles these pathways play in CSC populations of lung 
cancers. 
B cell-specific Mo-MuLV integration site 1 (Bmi1) is a member of the Polycomb group family 
of proteins and a downstream effector of the extracellular signaling molecule Shh. Bmi1 is 
implicated in the self-renewal of multiple stem cells including hematopoietic and neural 
stem cells [84]. Dovey, et al. [85] suggested that Bmi1 is critical for both normal and tumor 
bronchioloalveolar stem cell expansion in mice. Koch, et al. [69] demonstrated that a 
majority of SCLCs were immunohistochemically positive for antibodies against Bmi1. From 
these results, they hypothesized that Bmi1 is a potential CSC marker of SCLC. 
A couple of studies suggest that Oct-4 is a potential CSC marker for lung cancers. Levina, et 
al. [50] demonstrated that a human large cell cancer cell line (H460) propagated a CSC-like 
cell population that showed CD133, Oct-4, and high nuclear β-catenin expression after an in 
vitro treatment with anti-cancer drugs. Chen, et al. [51] reported that Oct-4 expression plays 
a crucial role in maintaining the self-renewing, CSC-like, and chemo-radio-resistant 
properties of CD133-positive NSCLC cell lines. Oct-4 is a member of the POU transcription 
factor family known to be expressed in pluripotent stem cells and to function as a 
transcriptional regulator of multiple genes related to stemness [86]. 
In vitro assay 
Several in vitro assays have been used to identify CSCs, including sphere-formation assays, 
serial colony-forming unit assays (re-plating assays), and label-retention assays [10,14]. 
Among them, sphere-formation assays are utilized in a wide range of tissue systems 
including lung cancers [42,87]. However, each of these methods has potential pitfalls that 
complicate interpretation of the results. For instance, difficulty in confirming clonality 
(single cell origin) has been pointed out [10]. In addition, the culture conditions used for 
these assays potentially exert selection pressures upon the cultured cells, resulting in the 
selection of only cell populations that are able to survive and proliferate under such specific 
conditions. The limitations of these in vitro assays should be kept in mind, and a 
combination of methods including in vivo assays is necessary for the identification and 
isolation of CSCs. 
CSC niche 
The microenvironment surrounding normal and cancer stem cells, which provides the stem 
cell niche, plays multiple roles including as a mechanical anchorage for the stem cells and in 
cross-talk communication mediated by direct contact and/or indirect extracellular factors. 
For instance, Wnt ligands are produced and released from both stem cells and niche cells, 
BMP and Shh are released from niche cells and epithelial cells respectively, and Notch 
signaling is transmembranously transmitted between neighboring cells. The 
microenvironment may also provide signaling via the cell receptor integrin as suggested by 
its expression in prostatic CSCs [88] and its co-expression with AC133 (CD133) in the 
epidermal basal cells [36], as well as through metalloprotease-mediated lysophopholipid 
signaling [89]. 
The concept of a CSC niche is a matter of debate [90]. Two fundamental questions need to be 
answered: 1) Does a specific CSC niche exist? 2) If it does, what are the differences between 
the normal stem cell niche and CSC niche? Sneddon, et al. [23] removed some of the 
confusion regarding the CSC niche by proposing several possible models (Figure 1): 1) CSCs 
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are capable of surviving in the normal stem cell niche, 2) a distinct CSC niche is necessary 
for activation, 3) CSCs may be capable of providing signals that instruct an otherwise 
quiescent niche to become activated (“hijacking the niche”), 4) CSCs could amplify an 
already existent activated niche, 5) CSCs may be niche-independent, that is, they themselves 
acquire the ability to maintain activity, and 6) there may be a discrete niche that is inhibitory 
for CSC maintenance. Accumulating evidence suggests that no single model fits all the 
diverse types of cancer. Further study is required to establish a universally acceptable CSC 
niche theory. 
While the niche may also play an important role in the maintenance of CSCs from lung 
cancers, little has been elucidated yet. Hilbe, et al. [91] demonstrated by 
immunohistochemistry a significant increase in CD133-positive vascular endothelial cells in 
patients with NSCLC and suggested an involvement of endothelial progenitor cells in the 
tumor vasculature and tumor growth, as well as possibly the maintenance and activation of 
CSCs. More studies of the lung CSC niche are required not only to understand the biological 
relationship between lung CSCs and their niche but also for the development of therapeutic 
strategies for lung cancers. 
Brief summary of lung CSC markers and potential problems 
While investigations into the CSC markers of lung cancer are insufficient at this time, as 
discussed above and summarized in Table 1, we tentatively summarize the findings to date 
as follows: 1) CD133 expression and the SP phenotype are common CSC markers for SCLC 
and NSCLC. 2) The Wnt/β-catenin signaling pathway is also important in the maintenance 
and activation of CSCs in SCLC and NSCLC. 3) PODXL-1 and uPAR are potential CSC 
markers for SCLC, but their expression has not been well examined in NSCLC. 4) In regard 
to ALDH, results reported to date appear to be complicated. Its enzymatic activity has been 
demonstrated in SCLC and NSCLC cells by the Aldefluor assay, as well as by a 
spectrophotometrical assay [92-97]. On the other hand, an immunohistochemical analysis 
using antibodies against ALDH1A1 and ALDH3A1 in tissue sections of surgical specimens 
of lung cancer demonstrated the expression of these ALDH isozymes in NSCLC cases, but 
not in SCLC cases, suggesting that the ALDH protein expression was limited to CSCs in 
NSCLC [96]. In contrast, Moreb, et al. [93] reported that in their studies using several SCLC 
and NSCLC cell lines there were good correlations between the results of a Western blot 
analysis, a spectrophotometrical analysis, and the Aldefluor assay, in spite of a few 
exceptions (see below). The discrepancy among these results may be attributable to the 
difference in the antibodies used, and the difference between the in vitro and in vivo 
conditions as well. 
Though evidence is still poor, it is supposed that distinct differences in the mechanism of 
ALDH expression and activity, as well as the role of ALDH in the maintenance/activation 
of CSCs, exist between SCLC and NSCLC. Furthermore, the exact mechanism and role of 
ALDH in the maintenance of the stemness of normal stem cells and CSCs are still unknown. 
To try to resolve these issues, we have carried out investigations, which are described in the 
following section. 
Recent findings in ALDH and CSC of the lung  
As described above, ALDH activity and its protein expression have been reported to be 
useful normal stem cell and CSC markers in a wide range of tissues [66,92,96-98]. These 
www.intechopen.com
Cancer Stem Cells in Lung Cancer: 
Distinct Differences between Small Cell and Non-Small Cell Lung Carcinomas   
 
113 
ALDHs play pluripotent roles in endobiotic and xenobiotic metabolism through specific 
metabolic pathways. One important issue to be addressed is which ALDH isozymes are 
responsible for the ALDH activity used to identify stem cell progenitors. Several studies 
have demonstrated that ALDH activity is needed for the differentiation of primitive 
progenitors into mature cells, thus fulfilling one of the defining characteristics of 
multipotent stem cells, and some lines of evidence suggest that ALDH1A1 is an important 
marker of hematopoietic stem cell progenitors [92]. In fact, ALDH1A1 is one of the enzymes 
involved in the production of retinoic acid from retinol, and retinoic acid is considered 
significantly important in maintaining a balance between hematopoietic stem cell self-
renewal and differentiation [92]. 
Moreb, et al. [93] systemically evaluated ALDH expression in several lung cancer cells lines 
(SCLC and NSCLC cell lines) utilizing the Aldefluor assay, a Western blotting, and a 
spectrophotometry and found a very good correlation between the results of all three. They 
concluded that the Aldefluor assay can be adapted successfully to measure ALDH activity 
in lung cancer cells, providing real time changes in ALDH activity in viable cells treated 
with chemotherapy or siRNA. They emphasized the importance of the use of mixed 
populations of cells with high ALDH levels and cells lacking ALDH activity when ALDH 
activity is measured by the Aldefluor assay in cells known to have high ALDH levels. 
Importantly, they carried out double Aldefluor and propidium iodide (PI) staining to 
delineate dead cells. According to their results, while ALDH expression levels were 
heterogeneous among the cell lines examined, overall findings revealed low levels of ALDH 
activity in SCLC cell lines, while higher levels were detected in some, but not all, NSCLC 
cell lines. The results correlated very well with protein and enzymatic activity as measured 
by the Western blot analysis and the spectrophotometrical assay, respectively. Intriguingly, 
there was one exception: The SW210.5 (SCLC) cell line registered only a small amount of 
ALDH activity in the spectrophotometrical assay and expressed only small amounts of 
ALDH1A1 and ALDH3A1 proteins in the Western blot analysis, whereas the Aldefluor 
assay showed high levels of ALDH activity (50% of the cells). This SCLC cell line (SW210.5) 
was shown to express mRNA for ALDH1A1 and ALDH2, but not ALDH3A1, by the semi-
quantitative reverse transcription polymerase chain reaction (RT-PCR) assay. 
 Our preliminary experiments revealed very high levels of ALDH1A1 mRNA expression in 
some SCLC and NSCLC cell lines. We also observed considerable discrepancies between 
mRNA levels detected by the quantitative RT-PCR assay, protein levels analyzed by 
Western blotting, and the proportion of cells with enzymatic activity measured by the 
Aldefluor assay in several SCLC and NSCLC cell lines. 
Aiming to elucidate the mechanism underlying the discrepancies observed in preliminary 
experiments and the previous study, we carried out the following experiments. 
ALDH mRNA expression - its correlation with the most common CSC marker CD133 - 
The quantitative RT-PCR assay revealed that ALDH1A1 mRNA was expressed at detectable 
levels in seven out of nine SCLC cell lines (77.8%), three of which expressed it at 
unequivocally high levels (33.3%), while it was expressed in four of the 18 NSCLC cell lines, 
two of which expressed it at high levels (11.1%)(Figure 2). On the other hand, ALDH2 was 
expressed in eight of the nine SCLC cell lines and 17 of the 18 NSCLC cell lines. The levels 
were lower on the whole than those of ALDH1A1 and did not remarkably differ among the 
cell lines. mRNA of CD133, most commonly used CSC marker, was expressed only in SCLC 
cell lines (66.7%, six out of nine cell lines), and its level in SCLC cell lines tended to be 
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associated with the level of ALDH1A1, but not ALDH2. The findings suggested ALDH1A1 
to have an important significance in the maintenance of stemness in lung cancer cells, and 
might account for the highly malignant activity of SCLCs.   
ALDH protein expression in lung cancer cell lines  
ALDH protein was detected by Western blotting using a non-selective antibody, which 
binds both ALDH1A1 and ALDH2 proteins (clone 44, BD transduction, Palo Alto, CA). The 
protein was expressed at high levels in two of the nine SCLC cell lines (22.2%), and two of 
the 18 NSCLC cell lines (11.1%)(Figure 3). The level of protein paralleled well the level of 
ALDH1A1 mRNA, but not ALDH2 mRNA, in NSCLC cell lines, suggesting that the protein 
detected by the Western blot analysis was ALDH1A1 rather than ALDH2 (Figure 2 and 
Figure 3). Thus, we describe the protein detected here by the Western blot analysis as 
ALDH1A1. Interestingly, one SCLC cell line (Lu134) with a high level of ALDH1A1 mRNA 
did not express ALDH1A1 (either ALDH1A1 or ALDH2) (Figure 2). This result is similar to 
a previous observation that a SCLC cell line, SW210.5, expressed ALDH1 mRNA, but only a 
very small amount of protein [93]. These findings suggest a potential post-translational 
mechanism to be involved in ALDH1A1 protein expression in some SCLC cells.  
ALDH activity in lung cancer cell lines  
The fraction of cells with ALDH activity was measured with the Aldefluor assay. The two 
SCLC cell lines with high ALDH1A1 protein levels (H1688 and H1618) had fractions of cells 
with strong ALDH activity (Figure 4). All of the SCLC cell lines with very weak ALDH 
protein expression (the faint bands detected by Western blotting in these cell lines were 
presumably ALDH2, because these cell lines expressed only ALDH2, not ALDH1A1, 
mRNA) had only a small fraction (less than 10%) of cells with ALDH activity. On the other 
hand, among NSCLC cell lines examined (A549, PC1, H441, H2087 and H1299) (not all data 
shown), only one (PC1) had fraction of cells with strong ALDH activity (Figure 4). One cell 
line with high ALDH1A1 protein levels (A549) unexpectedly had only a very small fraction 
of cells with strong ALDH activity. Summarizing the findings, ALDH1A1 protein 
expression was closely associated with ALDH activity in SCLC cells, but not necessarily in 
NSCLC cells, suggesting the potential post-translational mechanism to be involved in 
activation of ALDH1A1 protein in NSCLCs.  
Primary structure of ALDH1A1 mRNA 
To elucidate the possible involvement of a mutation (or polymorphism) or splicing disorder 
in the difference among the levels of mRNA, protein and activity, which was observed in 
Lu134 SCLC and A549 NSCLC cells, the nucleotide sequence of open reading frames of 
cDNA were analyzed. No mutation (or polymorphism) causing an amino acid substitution 
was found in either cell line (data not shown). However, interestingly, short mRNA variant 
(258 base pairs in the open reading frame, encoding 86 amino acids: see Figure 5) was found 
in the Lu134A cell line. This variant was found in three of eight sub-clones (37.5%) in our 
sub-cloning experiment (part of the result is shown in Figure 5). The result suggested the 
possible involvement of such a variant in the post-transcriptional regulation of ALHD1A1 
expression, and also implied a potential difference between SCLC and NSCLC, although 
further screening of a larger number of cell lines and primary lung cancers is required to test 
this idea.    
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Post-translational modification of ALDH1A1 protein 
Since no mutation was found in the cell line with the lag between ALDH1/2 protein 
expression and ALDH activity (A549 cells), we next verified the possible involvement of a 
post-translational modification. To screen for such a modification, two-dimensional Western 
blot analysis was performed with A549 (NSCLC) and H1688 (SCLC) cells (Figure 6). While 
the results did not reveal unequivocal evidence of a modification, the ALDH1A1 protein 
migrated slightly faster in A549 cells (Figure 6). To elucidate the mechanism underlying the 
lag between ALDH1A1 protein expression and ALDH activity, further investigations of 
protein structure and modifications such as glycosylation, phosphorylation and acetylation 
status, are required.   
ALDH protein expression in primary lung cancers 
ALDH protein expression in primary lung tumors was examined by immunohistochemistry 
using a non-selective antibody (clone 44, BD transduction, Palo Alto, CA), which binds both 
ALDH1A1 and ALHD2 proteins (ALDH1/2). The protein expression was detected in three 
of nine SCLCs (33.3%) and in 41 of 70 NSCLCs (58.6%)(Table 2). The levels tended to be 
higher in NSCLC, especially SQC, than in SCLC (Figure 5). The results were similar to those 
reported by Patel, et al. [96], who found in their immunohistochemical analysis that the 
ALDH isozymes 1A1 and 1A3 were expressed at significantly higher levels in NSCLC than 
in SCLC [96]. However, we have found that there is a discrepancy between the results of 
Western blotting for cancer cell lines and immunohistochemistry for primary lung cancers. 
The frequency of ALDH1/2 protein expression was considerably higher in primary cancers 
than in cell lines among NSCLCs, whereas it was similar between the two among SCLCs 
(Figure 3 and Table 2). Moreover, non-cancerous airway cells in vivo, i.e., both the bronchial, 
bronchiole and alveolar epithelial cells, exhibited high levels of immunohistochemical 
expression of ALHD1/2 protein compared to cancer cells in all cases examined (Figure 7 
and Table 2). Interestingly, the two non-cancerous immortalized airway epithelial cell lines 
(NHBE-T and HPL1D) showed very weak expression of ALDH1/2 protein in vitro. The 
ALDH family is expressed in response to toxic stress [99-101]. The marked expression of 
ALDH1/2 protein in non-cancerous airway epithelial cells in vivo is supposed to be induced 
by external stimuli such as dust, cigarette smoke and so on. In NSCLCs, ALDH1/2 protein 
tended to be expressed more strongly among in situ parts than invasive parts (data not 
shown), in support of our supposition. Furthermore ALDH1/2 protein expression tended to 
decrease in parallel with the dedifferentiation process, as a large proportion of poorly 
differentiated NSCLCs expressed the protein only faintly (data not shown). In well-
differentiated and in situ NSCLCs, ALDH1/2 expression may still be regulated by the 
physiological system (it may be lost during progression process to develop poorly 
differentiated ones). Although further investigation is required to elucidate the mechanism 
and significance of such a downregulation of ALDH1/2 protein expression in primary lung 
cancers, the results obtained here imply that ALDH1/2 protein plays diverse roles in 
different situations is not a universal stem cell marker. The mechanism to induce ALDH1/2 
protein expression and its significance are likely to differ among the non-cancerous airway 
epithelia, NSCLCs and SCLCs.  
10. Conclusion 
As is widely accepted, among lung cancers, SCLC and NSCLC are distinctly different in 
terms of biological behavior and pathogenesis. We have hypothesized that the CSCs of these 
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two major subtypes of lung cancer possess different biological properties and that the 
abundance of CSCs population differs between the two. We have here focused upon ALDH 
to confirm such a potential difference. 
The proportion of cells with strong ALDH activity tended to be associated with the CD133 
mRNA level especially in SCLC cell lines (Figure 2). Recently, Jiang, et al. [52] demonstrated, 
in SCLC cell lines, that the ALDH1A1high-CD133high-ASCL1high subpopulation exhibits the 
features of CSCs and that ASCL1 directly regulates ALDH1A1 and CD133 both in vitro and 
in vivo. Previous observations [60] are consistent with our results and also support the 
hypothesis that the size of the CSC fraction (population) could be one causes of highly 
malignant activity of SCLC. Importantly, however, not all SCLCs among cell lines and 
primary tumors were found to have either protein expression or a fraction of cells with high 
ALDH activity (Figure 4, Figure 7 and Table 2). We thus speculate that the ALDH activity is 
only one of the factors determining the stemness of CSCs in SCLCs. Alternatively, 
ALDH1A1 protein expression or ALDH activity is just part of the machinery to maintain 
stemness and might have significance only in some fractions of SCLCs. On the other hand, 
Ucar, et al. [95] proposed ALDH activity to be a CSC marker in a NSCLC cell line (NIH-H522 
LCC cell line). Moreover, Jiang, et al. [49] reported that, in NSCLCs, cancer cells with strong 
ALDH1A1 activity, which were isolated using the Aldefluor assay followed by fluorescence-
activated cell sorting, showed CSC features and CD133 expression. They proposed that 
ALDH1A1 is a lung cancer stem cell-associated marker, being a potential prognostic factor 
and therapeutic target for the treatment of patients with lung cancer. In our experiments, 
one NSCLC cell line (PC1 [SQC]) had a high ALDH1A1 protein level and a large fraction of 
cells with strong ALDH activity (Figure 3 and Figure 5), but did not express CD133 mRNA. 
Taken together, it is supposed that there is considerable heterogeneity in the mechanism 
maintaining the stemness of CSCs of SCLCs and NSCLCs.   
Aside from the maintenance of stemness, another interesting finding of our experiments was 
that the level of ALDH1A1 mRNA did not always parallel the level of protein in SCLC cell 
lines, whereas, in NSCLC cell lines (Figure 3 and Figure 4), the level of protein was not 
always consistent with that of activity. Furthermore, the in vivo findings revealed that either 
non-cancerous airway epithelia or low-grade neoplasms such as well-differentiated or in situ 
NSCLCs showed stronger immunohistochemical expression of ALDH1A1 (possibly ALDH2 
too) protein than less-differentiated cancer cells. 
From the current findings, the mechanism and pathway which regulate the expression of 
ALDH1A1 mRNA and its protein as well as its enzymatic activity, and its role vary in 
different situations and among non-cancerous airway cells, NSCLCs and SCLCs, as well as 
among individual tumors. We speculate that ALDH1A1, its expression and/or activity, is 
only one of the factors determining the stemness in lung cancers.  
In conclusion, the CSCs in SCLC and NSCLC differ distinctly from each other in terms not 
only of their abundance (suggested by CD133 mRNA levels) but also of the regulatory 
mechanism of ALDH1A1 expression and its activity, as well as its role in the 
maintenance/activation of stemness. The investigation of the mechanism of ALDH 
activation and its role in the maintenance of the stemness not only of CSCs but also of 
normal stem cells would provide a novel paradigm for stem cell biology and the 
development of a molecular targeting therapy for lung cancer. 
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Fig. 1. Hypothesis for the relationship between cancer stem cells (CSCs) and their niche. At 
least one genetic or epigenetic event (yellow arrow) is required to occur in a normal stem 
cell (NSC; or progenitor cell, not shown here) for a CSC initiation to develop (closed 
arrows). The CSCs may utilize the normal niche (1), require the distinct CSC niche (2), 
instruct an otherwise quiescent niche to become activated by providing signals (“hijacking 
the niche”) (3), amplify an already existent activated niche (4), or become niche-independent 
(5). Furthermore, there may be a discrete niche that is inhibitory for CSC maintenance (6). 
(Modified from [24]). 
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Fig. 2. Expression of ALDH1, ALDH2 and CD133 mRNA in immortalized human airway 
cell and lung cancer cell lines. Levels of mRNA of ALDH1, ALDH2 and CD133 and β-actin 
(ACTB) were measured by quantitative RT-PCR.  The mRNA levels of ALDH1 (upper 
panel), ALDH2 (second panel) and CD133 (lower panel) relative to that of ACTB in 
immortalized human airway cells and lung cancer cells are presented. IMC, immortalized 
human airway cell lines; ADC, adenocarcinoma cell lines; SQC, squamous cell carcinoma 
cell lines; LCC, large cell carcinoma cell lines; NSCLC, non-small cell lung carcinoma cell 
lines; SCLC, small cell lung carcinoma cell lines. The experimental materials and methods 
are as follows. An immortalized human airway epithelial cell line (16HBE14o, Simian virus 
40 (SV40)-transformed human bronchial epithelial cells) described by Cozens AL, et al. [102] 
was kindly provided by Gruenert DC (California Pacific Medical Center Research Institute, 
CA) via Kaneko T (Division of Respiratory Disease Center, Yokohama City Medical Center 
Hospital, Yokohama, Japan). A sub-clone of 16HBE14o cells, described as NHBE-T in this 
chapter, was used. An immortalized airway epithelial cell line (HPL1D, SV40-transformed 
human small airway epithelial cells) established by Masuda A, et al. [103], was provided by 
Takahashi T (Division of Molecular Carcinogenesis, Center for Neurological Disease and 
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Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan). Human lung 
cancer cell lines (A549, H358, H2087, H1618, H1688 and H1299) were purchased from 
American Type Culture Collection (ATCC, Manassas, VA). Human lung cancer cell lines, 
LC2/ad, Lu134A and Lu140 were obtained form Riken Cell Bank (Tsukuba, Japan), and 
PC9, PC1 and HARA from Immuno-Biological Laboratories Co. (Gunma, Japan). Human 
lung cancer cell lines, TKB1, TKB2, TKB4, TKB5, TKB6, TKB7, TKB8, TKB12, TKB15, TKB16, 
TKB17 and TKB20, were kindly provided by Kamma H (Department of Pathology, Kyorin 
University School of Medicine, Tokyo, Japan) via Yazawa T (Department of Pathology, 
Yokohama City University School of Medicine, Yokohama Japan). The cells were cultured 
and grown in DEMEM (Sigma Aldrich, St. Louis, MO) (NHBE-T, HPL1D, A549, H358, 
H2087, PC9, PC1, HARA, LC2/ad, TKB1, TKB2, TKB4, TKB5, TKB6, TKB7, TKB8, TKB20 
and H1299) or RPMI1640 medium (Sigma) (H1618, H1688, Lu130, Lu134A, Lu140, TKB12, 
TKB15, TKB16 and TKB17) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) (Sigma), 100 units/ml of penicillin (Sigma), and 100 μg/ml of streptomycin (Sigma). 
Total RNA was extracted from the cells with Isogen reagents (NIPPON GENE, Tokyo, 
Japan). First-strand cDNA was synthesized from total RNA using the SuperScript First-
Strand Synthesis System according to the protocols of the manufacturer (Invitrogen, 
Carlsbad, CA). The cDNA generated was used as a template in real-time PCR with SYBR 
Premix EXTaq (Takara, Kyoto, Japan). The primer set used for ALDH1A1 was forward (F), 
5’- agtgcccctttggtggattc; reverse (R), 5’- aagagcttctctccactcttg.  That for ALDH2 was, F, 5’- 
ctacacacgccatgaacctg; R, 5’- caaccacgtttccagttg. That for CD133 was, F, 5’- 
ttgtggcaaatcaccaggta; R, 5’- gatgttgggtctcagtcggt. That for ACTB was, F, 5’-
tggcacccagcacaatgaa; R, 5’- ctaagtcatagtccgcctagaagca. The mean of the copy number of 
ALDH1A1, ALDH2 or CD133 normalized to the value for ACTB mRNA was obtained from 
triplicate reactions.   
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Fig. 3. Expression of ALDH1A1/ALDH2 (ALDH1/2) protein in lung cancer cell lines. 
ALDH1/2 (top panel) and β-actin (ACTB) (second panel) protein expressions were analyzed 
by Western blotting. Levels of ALDH1/2 and ACTB protein were semi-quantified with a 
densitometer (NIH Image; National Institute of Mental Health at Bethesda, MD). The level 
of ALDH1/2 normalized to that of ACTB is presented in a graph (third panel). IMC, 
immortalized human airway epithelial cell lines; ADC, adenocarcinoma cell lines; SQC, 
squamous cell carcinoma cell lines; LCC, large cell carcinoma cell lines; NSCLC, non-small 
cell lung carcinoma cell lines; SCLC, small cell lung carcinoma cell lines. The experimental 
materials and methods are as follows. The cell lines (the details of the experimental 
materials are described in the legend for Figure 2) grown to sub-confluence were solved 
with extraction buffer, as described elsewhere [104]. After centrifugation, supernatants 
were recovered as protein extracts. The extracts were mixed with equal volumes of 
2×sample buffer [104], and then boiled. The samples were subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis, and transferred onto PVDF membranes 
(Amersham, Arlington Heights, IL). The membranes were incubated with nonfat dry milk 
in 0.01 M Tris-buffered saline containing 0.1% Tween-20 (TBS-T) to block non-
immunospecific protein binding, and then with 0.1 μg/ml of a primary antibody which 
non-selectively binds to both ALDH1A1 and ALDH2 (clone 44, BD Transduction, San Jones, 
CA) or a primary antibody against ACTB (Sigma). After washing with TBS-T, the 
membranes were incubated with animal-matched horseradish peroxidase-conjugated 
secondary antibodies (Amersham). Immunoreactivity was visualized with the enhanced 
chemiluminescence system (ECL, Amersham). 
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Fig. 4. Measurement of fraction of cells with ALDH activity (Aldefluor assay) in lung cancer 
cell lines. Cells were labeled with Aldefluor (BODIPY-aminoacetaldehyde [BAAA]) (Stem 
cell technology Inc., Vancouver, Canada) with or without the ALDH inhibitor 
diethylaminobenzaldehyde (DEAB) (Stem cell technology). The proportion of fraction of 
cells with ALDH activity was measured by flow cytometer. The X-axis is fluorescence 
intensity (log scale), and the Y-axis is forward scatter level (linear scale). The fraction of cells 
with strong ALDH activity is shown (red circle). NSCLC, non-small cell lung carcinoma cell 
lines; ADC, adenocarcinoma cell lines; SQC, squamous cell carcinoma cell lines; SCLC, small 
cell lung carcinoma cell lines. The experimental materials and methods are as follows. The 
details of the cell lines examined are described in the legend for Figure 1. Cells with ALDH 
activity was labeled using Aldefluor assay kit (Stem cell technology) according to the 
manufacturer’s instructions. Briefly, 1.0×106 cells in 1 ml of Aldefluor assay buffer with 
BAAA at a concentration of 1.5 mM were incubated for 45 min at 37C. In each experiment, a 
sample of cells was treated under identical conditions with 50 mM of a specific ALDH 
inhibitor (DEAB) to serve as a negative control. The fraction of cells with ALDH activity 
labeled by Aldefluor was measured with a flow cytometer (BD Science, San Jose, CA) 
(excitation wave length 488 nm and emission wave length 525 nm (green fluorescence)). 
Data for 1.0×105 cells were collected.   
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Fig. 5. Analysis of primary structure of mRNA of ALDH1A1. The protein-coding sequence 
in ALDH1A1 mRNA was amplified by RT-PCR using primers, forward, 5’-
aggagccgaatcagaaatgtc; reverse, 5’-aagagcttctctccactcttg, according to the method descried in 
the legend for Figure 2. The PCR product was sub-cloned into the plasmid vector pT7Blue 
(Novagen, Darmstadt, Germany), and then its size was checked by PCR using universal 
primers (T7 promoter primer and M13M4 primer (Novagen)). (A) A representative result 
from A549 (ADC) and Lu134A (SCLC) cells is shown. Shorter PCR products (faster 
migrating band (asterisk)) were found in some sub-clones from Lu134A. Bands of expected 
size with a full-length coding region of ALDH1A1 (NCBI accession # NM_000689) are 
indicated with an arrow. (B) Schema of the primary structure of the consensus mRNA and 
the shorter variant with their mRNA spliced sites in the ALDH1A1 gene, is shown. The 
shorter novel variant consists of parts of exon 1, exon2, exon 11, exon 12, and exon 13. “ex” 
in figure means exon.       
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Fig. 6. Two-dimensional Western blotting analysis of ALDH1A1/ALDH2 (ALDH1/2) 
protein in a NSCLC cell line (top panel; A549) and SCLC cell line (Bottom panel; H1688). 
Spots of ALDH1/2 protein were circulated with dashed lines. MW, molecular weight; KD, 
kilo-dalton; pI, isoelectric point plugin. The experimental materials and methods are as 
follows. Two-dimensional electrophoresis (2-DE) was carried out using a horizontal 
electrophoresis system (Maltiphor II; Amersham) according to the manufacture’s 
instruction. Briefly, equal amount of protein sample was subjected to the first-dimensional 
isoelectric focusing, and followed by the second dimensional sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. The details of method are described elsewhere [105,106]. 
The separated proteins on the 2-DE gels were transferred onto a polyvinylidene difluoride 
membrane (FluoroTrans® PVDF Membrane, Nippon Genetics, Tokyo, Japan). The 
membranes were incubated with nonfat dry milk in 0.01 M Tris-buffered saline containing 
0.1% Tween-20 (TBS-T) to block non-immunospecific protein binding, and then with 0.1 
μg/ml of a primary antibody, which non-selectively binds to both ALDH1A1 and ALDH2 
(clone 44, BD Transduction). After washing with TBS-T, the membranes were incubated 
with animal-matched horseradish peroxidase-conjugated secondary antibodies 
(Amersham). Immunoreactivity was visualized with the enhanced chemiluminescence 
system (ECL, Amersham). 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
www.intechopen.com
Cancer Stem Cells in Lung Cancer: 
Distinct Differences between Small Cell and Non-Small Cell Lung Carcinomas   
 
125 
 
 
 
 
 
Fig. 7. Expression of ALDH1A1/ALDH2 (ALDH1/2) protein in non-cancerous airway 
epithelia and primary lung cancers. (A) Representative photographs of 
immunohistochemistry of surgical specimens of non-cancerous airway epithelia (top panels) 
and lung cancers (the other panels) are shown. Magnifications are ×200 in, non-cancerous 
airway epithelia (bronchus, bronchiole and alveolus), adenocarcinoma (ADC), squamous 
cell carcinoma (SQC) and small cell lung carcinoma (SCLC), and ×400 in the inset of SCLC. 
Levels of ALDH1/2 expression were evaluated according to a scoring system; negative 
(score 0), unequivocally strong (score 2), and positive but weaker than a score of 2 (score 1). 
(B) Seventy-nine tumors (49 ADCs, 16 SQCs, 5 large cell carcinomas, and 9 SCLCs) were 
examined. The mean and standard deviation (error bar) among each histological type are 
shown in graph. Differences were analyzed with Student’s t-test, and P value is indicated. 
The experimental materials and methods are as follows. All cases examined were of lung 
cancer patients who underwent surgical resection at the Kanagawa Prefectural 
Cardiovascular and Respiratory Disease Center Hospital (Yokohama, Japan) between 2001 
and 2008. Informed consent for research use was obtained from all the subjects providing 
materials. Tissue sections (4 μm thick), cut from the formalin-fixed and paraffin-embedded 
tissue block with largest tumor dimension, were deparaffinized and rehydrated, and 
incubated with 3% hydrogen peroxide to block endogenous peroxidase activities. The 
sections were incubated with 5% goat serum to block non-immunospecific protein binding. 
After antigen retrieval treatment, boiling in citrated buffer (0.01 M, pH6.0) to restore the 
masked epitope, the sections were incubated with a primary antibody, which non-
selectively binds to both ALDH1A1 and ALDH2 (clone 44, BD Transduction). 
Immunoreactivity was visualized with an Envision detection system (DAKOcytomation, 
Carpinteria, CA), and the nuclei were counterstained with hematoxylin. 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
126 
 
Table 1. Cancer stem cell markers in small cell lung carcinoma amd non-small cell lung 
carcinoma 
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Table 2. Positive rate of immunohistochemical ALDH1/2 expression among NSCLC and 
SCLC 
Abbreviations 
SCLC: small cell lung carcinoma; NSCLC: non-small cell lung carcinoma; SQC: squamous 
cell carcinoma; ADC: adenocarcinoma; LCC: large cell carcinoma; RB: retinoblastoma; TP53: 
tumor protein 53; EGFR: epidermal growth factor receptor; ASCL1: achaete-scute complex 
homolog 1; TTF-1: thyroid transcription factor-1; ALDH: aldehyde dehydrogenase; CSC: 
cancer stem cell; ABCG2, ATP binding cassette transporter superfamily member G2; CIC: 
cancer initiating cell; SP: side population; FACS: fluorescence activating cell sorting; UV: 
ultraviolet; uPAR: urokinase plasminogen activator receptor; uPA: urokinase plasminogen 
activator; Shh: Sonic hedgehog; BMP: bone morphogenetic protein; Bmi1: B cell-specific Mo-
MuLV integration site 1; PODXL-1: podocalyxin-like protein 1; RT-PCR: reverse 
transcription polymerase chain reaction; mRNA, messenger ribonucleic acid: cDNA; 
complementary deoxyribonucleic acid; siRNA: small interfering RNA; PI: propidium iodide.  
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